Abstract: A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in ?179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×105 parathyroid live cells in the TheraCyte to manufacture the therapeutic microencapsulation; (3) implanting the therapeutic microencapsulation into a mammal object inside hypoderm, wherein the parathyroid live cells are not rejected and can last alive for four months; and (4) the therapeutic microencapsulation continues to generate parathyroid hormone to increase bone mineral density so as to avoid side effects, such as raising the level of calcium or lowering the level of phosphorus in blood.

Abstract: A therapeutic microencapsulation for embedding parathyroid live cells with TheraCyte® and a manufacturing method are disclosed, where in the agent is made by embedding at least 4×105 parathyroid live cells with TheraCyte®. The achieved agent can be planted into mammal objects for treating osteoporosis in long-term. The manufacturing method is characterized by immerging the parathyroid live gland in composition of Roswell Park Memorial Institute solution (85%), dimethyl sulfoxide (10%) and fetal calf serum 5% and depositing in ?179° C. liquid nitrogen. The frozen parathyroid gland is sliced to pieces to isolate the live cells after unfreezing and then the parathyroid live cells are embedded with TheraCyte® to achieve the therapeutic microencapsulation.